MANCHESTER, England--(BUSINESS WIRE)--DxS Ltd, a personalised medicine company and leaders in the provision of companion diagnostics, has announced it is working closely with AstraZeneca to make available a companion diagnostic for use with IRESSA™ (gefitinib), AstraZeneca’s treatment for non small cell lung cancer (NSCLC).
